Viewing data from:

ESCITALOPRAM OXALATE

ANDA

ESCITALOPRAM OXALATE | A090939 | TORRENT PHARMACEUTICALS LTD

3 strengths0 unique patents0 unique exclusivities

Reference Listed Drug: LEXAPRO(TE code: AB)

Drug Pricing (NADAC)

National Average Drug Acquisition Cost — Week of 2026-07-15 | 14 NDCs

Highest NADAC/Unit

$0.0639

per ea

Lowest NADAC/Unit

$0.0394

per ea

Brand NDCs

Generic NDCs

NDC Description	NADAC/Unit	Unit	Type	Generic NADAC	Effective
00904642761ESCITALOPRAM 20 MG TABLET	$0.0639	EA	Generic	—	2026-06-17
13668013701ESCITALOPRAM 20 MG TABLET	$0.0639	EA	Generic	—	2026-06-17
13668013705ESCITALOPRAM 20 MG TABLET	$0.0639	EA	Generic	—	2026-06-17
13668013710ESCITALOPRAM 20 MG TABLET	$0.0639	EA	Generic	—	2026-06-17
82009003710ESCITALOPRAM 20 MG TABLET	$0.0639	EA	Generic	—	2026-06-17
13668013505ESCITALOPRAM 5 MG TABLET	$0.0421	EA	Generic	—	2026-06-17

Showing 6 of 14 NDCs.

Source: NADAC (data.medicaid.gov). Prices reflect national average acquisition costs for retail community pharmacies.

VA Federal Supply Schedule

Government-negotiated contract prices | 1 NDC (1 FSS)

Lowest Price

$11.05

Highest Price

$11.05

FSS NDCs

Big4 NDCs

Description	Price	Type	Vendor	Contract End
00904-6426-61ESCITALOPRAM OXALATE 10MG TAB,UD	$11.05	FSS	The Harvard Drug Group L.L.C. dba Major Pharmaceuticals and Rugby Labs	05/31/2030

Source: VA Federal Supply Schedule (va.gov). Prices are government-negotiated contract prices.

API Supply Chain27 active DMFs8 inactive

24 active API suppliers hold Drug Master Files for this ingredient.

H LUNDBECK ASESCITALOPRAM OXALATE

DMF 141031999

CIPLA LTDESCITALOPRAM OXALATE USP

DMF 166362003

HETERO LABS LTDESCITALOPRAM OXALATE (PROCESS-I)

DMF 179602004

ZYDUS LIFESCIENCES LTDESCITALOPRAM OXALATE USP

DMF 181192005

MATRIX PHARMACORP PRIVATE LTDESCITALOPRAM OXALATE USP

DMF 182132005

APITORIA PHARMA PRIVATE LTDESCITALOPRAM OXALATE USP

DMF 190882005

JUBILANT BIOSYS LTDESCITALOPRAM OXALATE USP

DMF 194462006

NEULAND LABORATORIES LTDESCITALOPRAM OXALATE

DMF 196622006

ARCH PHARMALABS LTDESCITALOPRAM OXALATE

DMF 196632006

ZHEJIANG HUAHAI PHARMACEUTICAL CO LTDESCITALOPRAM OXALATE USP

DMF 200812006

CADILA PHARMACEUTICALS LTDESCITALOPRAM OXALATE USP

DMF 224402009

JUBILANT BIOSYS LTDESCITALOPRAM OXALATE USP (ESP PROCESS)

DMF 228642009

MACLEODS PHARMACEUTICALS LTDESCITALOPRAM OXALATE

DMF 229002009

WUXI JIDA PHARMACEUTICAL CO LTDESCITALOPRAM OXALATE

DMF 255192011

DR REDDYS LABORATORIES LTDESCITALOPRAM OXALATE (PROCESS II)

DMF 258732012

HETERO LABS LTDESCITALOPRAM OXALATE (PROCESS II)

DMF 261852012

RAKS PHARMA PVT LTDESCITALOPRAM OXALATE, USP

DMF 269672013

HEC PHARM CO LTDESCITALOPRAM OXALATE NON-STERILE BULK SUBSTANCE

DMF 284542014

MICRO LABS LTDESCITALOPRAM OXALATE USP

DMF 345682020

RUYUAN HEC PHARM CO LTDESCITALOPRAM OXALATE NON-STERILE BULK DRUG SUBSTANCE

DMF 351832020

VIRUPAKSHA ORGANICS LTDESCITALOPRAM OXALATE

DMF 366322022

CIPLA LTDESCITALOPRAM OXALATE USP (PROCESS-II)

DMF 389762023

SHODHANA LABORATORIES PRIVATE LTDESCITALOPRAM OXALATE

DMF 392002023

SMS PHARMACEUTICALS LTDESCITALOPRAM OXALATE USP

DMF 407212024

ZHEJIANG HAISEN PHARMACEUTICAL CO LTDESCITALOPRAM OXALATE

DMF 409232025

SYNERGENE ACTIVE INGREDIENTS PRIVATE LTDESCITALOPRAM OXALATE USP

DMF 410482025

MAITHRI LABORATORIES PRIVATE LTDESCITALOPRAM OXALATE USP

DMF 413152025

DR REDDYS LABORATORIES LTDInactiveESCITALOPRAM OXALATE

DMF 183422005

LUPIN LTDInactiveESCITALOPRAM OXALATE USP

DMF 191052005

SUN PHARMACEUTICAL INDUSTRIES LTDInactiveESCITALOPRAM OXALATE USP

DMF 192512006

SANDOZ PRIVATE LTDInactiveESCITALOPRAM OXALATE

DMF 227572009

CADILA HEALTHCARE LTDInactiveESCITALOPRAM OXALATE (FORM -1)

DMF 232342009

MICRO LABS LTDInactiveESCITALOPRAM OXALATE

DMF 246842010

IPCA LABORATORIES LTDInactiveESCITALOPRAM OXALATE

DMF 256602012

TOKUYAMA CORPInactiveESCITALOPRAM OXALATE

DMF 318072017

Source: FDA Drug Master Files (fda.gov). Type II API DMFs matched by ingredient.

Products (3)

Sort:

#001 — EQ 5MG BASE

0 patents0 exclusivities▴

TABLET;ORAL | Approved: Sep 11, 2012

No patent or exclusivity listings for this strength.

#002 — EQ 10MG BASE

0 patents0 exclusivities▾

TABLET;ORAL | Approved: Sep 11, 2012

#003 — EQ 20MG BASE

0 patents0 exclusivities▾

TABLET;ORAL | Approved: Sep 11, 2012